PETAL

Background

Phase III, open-label RCT (PETAL). 862 patients with previously untreated aggressive B-cell lymphoma (primarily DLBCL). All patients received 2 cycles of R-CHOP followed by interim PET-CT. The 597 PET-negative patients continued R-CHOP (with a separate randomization ± 2 extra rituximab doses). The PET-positive patients (poor early responders) were randomized to assess whether PET-guided intensification improved outcomes.

Interventions and follow up

PET-negative responders: R-CHOP × 6 cycles continuation, with randomization ± 2 additional rituximab doses
PET-positive randomization: R-CHOP continuation vs. Burkitt-like intensification (high-dose methotrexate, ifosfamide, etoposide, cytarabine)
Primary endpoint: 2-year EFS in interim-PET–positive aggressive B-cell lymphoma
Median follow up: ~6 years (long-term update)

Results

2-yr EFS (R-CHOP vs. Burkitt, PET-positive): 42.0% vs. 31.6%, HR 1.50 (95% CI 0.97–2.33), P=.12 — intensification numerically worse, not significant
PET-negative patients (n=597): 2-yr EFS ~80%
Extra rituximab in PET-negative group: no improvement in outcome
PET-positive at interim: inferior outcomes regardless of arm

Adverse events

Burkitt arm (grade ≥3): neutropenia 94%, infections 29%, mucositis 22%, neurologic toxicity 9%
R-CHOP arm (grade ≥3): 60%
Other: treatment-related mortality 2 in Burkitt arm vs. 0 in R-CHOP arm; significant dose delays in Burkitt protocol

Conclusions

PET-guided intensification to a Burkitt-like protocol in PET-positive DLBCL after 2 cycles of R-CHOP did not improve EFS (42% vs. 32%, HR 1.50, P=.12) and caused substantially more toxicity. Additional rituximab in PET-negative patients also did not help. This established that PET-positive early poor response cannot be rescued by intensification within the R-CHOP framework, while confirming interim PET as a strong prognostic marker.

Key Limitations

The PET-positive randomization was relatively small, leaving the comparison underpowered (wide CI crossing 1; P=.12), so a modest benefit or harm cannot be fully excluded. The Burkitt-like salvage regimen is highly toxic and not contemporary best-practice; results may not generalize to other intensification strategies (e.g., CAR-T, novel ADCs). Interim PET interpretation (Deauville cutoff) varied and the cohort included non-DLBCL aggressive histologies. PET-negative analyses were partly observational, limiting causal inference.

Clinical Context

PETAL is a landmark response-adapted DLBCL trial that, with GAINED and other interim-PET studies, established that interim PET is strongly prognostic but switching poor responders to intensified chemotherapy does not improve survival. Current ESMO/ASCO-aligned practice retains R-CHOP/Pola-R-CHP as backbone and does not endorse routine interim-PET–driven escalation; PET-positive disease is increasingly addressed with novel agents and cellular therapy at relapse. No drug approval derives from this academic trial.

References